This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
HAIFA, Israel, April 10, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the Company is scheduled to participate in several scientific and investment conferences in April 2013. To schedule a meeting with us upon availability, contact us at
Bizportal Biomed 2013 Conference
On April 10
th in Tel-Aviv, Zami Aberman, Chairman and CEO, will participate in a panel discussion entitled "Tel-Aviv New York, Gazing to the American Market and the Exit Dream" at the Bizportal Biomed 2013 Conference.
Regenerative Medicine Investor Day
On April 17
th in New York City, Mr. Aberman will present at the Regenerative Medicine Investor Day hosted by the
Alliance for Regenerative Medicine. The conference provides institutional, strategic and venture investors a unique opportunity to gain insight into the top regenerative medicine and advanced therapies companies.
Israstem, The Annual Israeli Meeting of Translational Research on Stem Cells, Cell Therapy and Regenerative Medicine in Industry and Academia
On April 22
nd – 23
rd, Dr. Ohad Karnieli, VP Development and Dr. Racheli Ofir, Intellectual Property & Senior Scientist, will chair a session entitled "Tools for Research and Development" and give a presentation entitled "A Harmonized Approach in the Regulation of PLX-PAD" respectively.
BIO-International 2013 Convention
From April 22
nd – 25
th, Mr. Aberman and Dr. William Prather, Sr. VP of Corporate Development, will participate in the BIO-International 2013 Convention in Chicago, Illinois. This popular biotechnology meeting is well attended by specialty and large pharmaceutical companies from all over the world.
19th ISCT Annual Conference
On April 24
th, Dr. Ohad Karnieli, VP Development, will give a presentation entitled "Challenges and Possible Solutions to Overcome the Gap in Critical Supply Chain Issues of New and Evolving Cutting Edge Technologies of Cell Therapy" at the Annual International Society for Cell Therapy Conference in Auckland, New Zealand.
International Advanced Course on Regenerative Medicine Manufacturing
From April 28
th - May 4
th, Lior Raviv, Team Lead Process Development, will lecture at the course on Regenerative Medicine Manufacturing in Tavira-Algarve, Portugal.
Needham Healthcare Conference
From April 30
th - May 1
st, Dr. Prather will attend the 12th Annual Needham Healthcare Conference held in New York City.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.